Health care stocks were climbing pre-bell Tuesday. The Health Care SPDR (XLV) was advancing by 0.6% and the iShares Biotechnology Index (IBB) was 0.9% higher recently.
Avidity Biosciences (RNA) was retreating by 18% after saying the US Food and Drug Administration placed a partial clinical hold on new participant enrollment for the phase 1/2 MARINA trial of its drug AOC 1001 in adults with myotonic dystrophy type 1 after a serious adverse event occurred in one participant.
Babylon Holdings (BBLN) was up more than 4% after the company and health insurance provider Bupa said they have extended a collaboration agreement to provide digital health services to Bupa's clients in the UK for three more years.
Ocular Therapeutix (OCUL) said its therapeutic candidate for wet age-related macular degeneration, OTX-TKI, was well tolerated and demonstrated a favorable safety profile during a Phase 1 clinical trial. Ocular Therapeutix was slipping past 8% recently.